Nosca Méréprine (Noscapine Hydrochloride Monohydrate)

Noscapine, the active ingredient in Nosca Méréprine, is an antitussive presented as an oral formulation for oral use. It acts as a non‑opioid cough suppressant that modulates the central cough reflex, providing relief of dry, non‑productive coughs in both adult and pediatric patients when indicated.

GNH USA supplies Nosca Méréprine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards for export. The product conforms to European Union pharmacopeial specifications and is manufactured under GMP conditions.

Noscapine is used as a non‑opioid antitussive that suppresses the cough reflex in various respiratory conditions.

- Non‑productive cough: reduces frequency and intensity of dry cough episodes. - Upper respiratory tract infection cough: offers symptomatic relief during viral colds. - Post‑viral cough: helps suppress lingering cough after viral illness.

Noscapine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: transient sensation of light‑headedness. - Headache: occasional mild headache. - Drowsiness: mild sedation, especially at higher doses. - Gastrointestinal discomfort: mild abdominal cramping or constipation.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, or swelling of the face and throat. - Hepatic enzyme elevation: rare increase in liver function tests. - Hematologic abnormalities: very rare cases of neutropenia or thrombocytopenia. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Anaphylaxis: extremely rare, rapid onset of systemic allergic response.

When considering Nosca Méréprine, several safety measures should be observed.

- Pregnancy: safety not established; avoid unless clearly needed. - Breastfeeding: unknown excretion; weigh benefits against potential risks. - Renal impairment: use with caution; monitor renal function. - Hepatic disease: consider dose adjustment; monitor liver enzymes. - Known hypersensitivity: discontinue if allergic signs appear. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Noscapine may interact with other medicines; awareness of the interaction level is important.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase noscapine plasma concentrations. - Co‑administration with other opioid‑containing antitussives (e.g., codeine): risk of additive central nervous system depression.

Moderate Interactions (Monitor Closely): - Sedatives or antihistamines: may enhance drowsiness. - MAO inhibitors: monitor for heightened central effects. - Drugs that prolong QT interval: observe cardiac rhythm. - Anticoagulants: potential alteration of bleeding risk. - Herbal supplements (e.g., St. John’s Wort): may affect metabolic pathways.